Doravirine/Islatravir for Initial HIV Therapy: A Two-Drug Strategy in a Three-Drug World
At CROI 2026, much of the discussion around antiretroviral therapy focused on long-acting agents and treatment optimization in experienced populations. Yet another important presentation turned to the starting point of care: initial therapy in people newly diagnosed with HIV.
25 February 2026 13:00
Simplifying the Complex: Switching to BIC/LEN in Treatment-Experienced People with HIV
At CROI 2026, among presentations focused on prevention strategies and new antiviral approaches, one oral session addressed a different — and very practical — question in HIV care: what about people who are already virologically suppressed but remain on complex, ...
More
24 February 2026 15:00
Syphilis, Superbugs and Self-Testing: STIs in the Era of HIV Control
At CROI 2026, alongside discussions of metabolic therapies and inflammation, another plenary session brought the audience back to a more familiar reality. In her lecture, “Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control,” ...
More
About Life4me+
One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis. So we talk about HIV and other diseases: how to protect yourself from them, how to live with them.
More
Campaign U=U (#UequalsU)
The information and education campaign "U=U" ("Undetectable equals untransmittable", #UequalsU, #НравноН), organized by Life4me + in the Eastern Europe and Central Asia region, aimed at disseminating information that an HIV-positive person with an undetectable viral load can not transmit the virus to another person sexually.
Many studies have shown that in a sero-discordant couple where the HIV-positive partner took ARV therapy and maintained an undetectable viral load, there were no reported cases of sexual transmission of HIV.
Our Partners
